Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney test could unlock better pain relief for sickle cell patients in crisis

NCT ID NCT07246265

Knowledge-focused Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how quickly the kidneys clear morphine in sickle cell patients having a painful crisis. Researchers will measure kidney function and morphine levels in 100 intensive care patients to see if higher doses are needed for effective pain relief. The goal is to personalize morphine dosing based on each patient's kidney function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient ≥ 18 years old * Known homozygous sickle cell disease SS, SC, S-beta+, or S-beta0 * Admitted in an intensive care unit * Clinical diagnosis of vaso-occlusive crisis and/or acute chest syndrome * Receiving PCA treatment with morphine * Patient's consent for study participation and/or from a relative if case of patient's incapacity * Affiliation to social protection Exclusion Criteria: * Patient previously included in the study during a previous stay * Injection of iodinated contrast medium outside the scope of the study within 24 hours prior to inclusion, or scheduled within 9 hours following the scheduled time of iohexol injection * Contraindication to iohexol: known or suspected immediate or delayed hypersensitivity, thyrotoxicosis. * Patient undergoing morphine treatment or substitution treatment such as methadone or buprenorphine prior to hospitalization (having received morphine or a derivative regardless of the route of administration in the week prior to hospitalization). * Chronic liver disease likely to interfere with morphine metabolism (cirrhosis ) * Any condition that contraindicates the use of morphine according to the summary of product characteristics * Patients under legal protection * Pregnant or breastfeeding women Exclusion criteria : * Need for extrarenal epuration within 24 hours of inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute chest syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute chest syndrome sickle cell disease Vaso-Occlusive Crises

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute chest syndrome Glomerular hyperfiltration Sickle cell disease Sickle cell nephropathy Vaso-occlusive crises

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Le Mans

    NOT_YET_RECRUITING

    Le Mans, 72000, France

  • CHRU de Tours

    RECRUITING

    Tours, France, 37044, France

  • CHU d'Orléans

    NOT_YET_RECRUITING

    Orléans, 45067, France

  • CHU de Nantes

    NOT_YET_RECRUITING

    Nantes, 44093, France

  • CHU de Rennes

    NOT_YET_RECRUITING

    Rennes, France

  • Henri-Mondor

    NOT_YET_RECRUITING

    Créteil, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.